Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Nurix Therapeutics (NASDAQ:NRIX) and maintained a $31 price target.
June 17, 2024 | 9:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Nurix Therapeutics and maintained a $31 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $31 price target by a reputable analyst suggests positive sentiment and confidence in Nurix Therapeutics' future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100